Boceprevir and Gengraf Capsules

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Boceprevir may increase the blood levels and effects of cycloSPORINE. You may need a dose adjustment if you have been taking cycloSPORINE and are starting treatment with boceprevir. Contact your doctor if your condition changes or you experience increased side effects such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, seizures, fever, sore throat, unusual bruising or bleeding, and increased or decreased urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may significantly increase the plasma concentrations of cyclosporine. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. The mechanism involves inhibition of CYP450 3A4, the isoenzyme responsible for the intestinal and hepatic metabolism of cyclosporine. Enhanced cyclosporine oral bioavailability due to inhibition of intestinal P-glycoprotein efflux transporter may also contribute. In 9 study subjects, administration of a single 10 mg dose of cyclosporine during treatment with telaprevir 750 mg every 8 hours for 11 days increased the dose-normalized cyclosporine peak plasma concentration (Cmax) and systemic exposure (AUC) by an average of 32% and 364%, respectively, compared to administration of a single 100 mg dose of cyclosporine alone. When a single 100 mg dose of cyclosporine was coadministered with boceprevir 800 mg three times a day for 7 days, cyclosporine Cmax increased by 2.0-fold and AUC increased by 2.7-fold. No significant effect on the pharmacokinetics of boceprevir was observed.

MANAGEMENT: Caution is advised if cyclosporine is used in combination with boceprevir or telaprevir. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of the HCV NS3/4A protease inhibitor. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Some authorities recommend against the use of telaprevir in organ transplant candidates or recipients.

Boceprevir

Generic Name: boceprevir

Brand name: Victrelis

Synonyms: Boceprevir (Oral)

What is Boceprevir?

Gengraf Capsules

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Gengraf (Capsules, Modified), Gengraf

What is Gengraf Capsules?